Close Menu

Van Andel Research Institute

The company plans to use the funding to support commercial growth of its molecular drug-matching service, OncInsights, which provides a searchable treatment report to community oncologists.

The Neuroblastoma and Medulloblastoma Translational Research Consortium will conduct a 14-patient trial in which it will try to pinpoint treatments that best suit individual participants based on their gene expression profiles.

The trial, which has been approved by the Food and Drug Administration and will begin enrollment immediately, will use next-generation sequencing and gene expression analysis to provide information about a patient's disease state and to identify targets for therapy.

The Van Andel Research Institute has created a pediatric cancer research program that will use personalized medical approaches for translational research.

The patent covers a "high-throughput method of screening for a biomarker indicative of a disease" and includes "methods utilizing a microarray to measure the glycan level of a protein."

IP Roundup: Nov 30, 2010

Premium

Fluidigm, Expression Analytics, Maven Technologies, Van Andel Research Institute, Industrial Technology Research Institute, Northwestern University, Bio-Rad Laboratories, Illumina, Aperio Technologies, Samsung Electronics

The company's Multiplexing Diagnostics division will use the arrayer to develop molecular tools, including protein biomarkers, to diagnose allergy and autoimmunity.

Pages

The Lancet and the New England Journal of Medicine have retracted two COVID-19 papers due to concerns about the data used in their analyses.

A new study finds that three dimensional facial scans may be able to aid in diagnosing rare genetic diseases.

Lawmakers plan to introduce a bill that aims to prevent the theft of US-funded research, according to the Wall Street Journal.

In Science this week: analysis of ancient Caribbean islanders' genomes suggests at least three waves of migration into the region,  DNA barcoding of microbial spores, and more.